Johnson & Johnson Debuts First Direct-to-Consumer Ad for Carvykti
Johnson & Johnson (J&J) has launched its first direct-to-consumer (DTC) advertisement for Carvykti, a CAR-T cell therapy used to treat multiple myeloma. The campaign, which will run on popular streaming platforms such as YouTube, Paramount, and Roku, is part of the company’s broader strategy to elevate awareness of advanced treatment options among patients who may not be under the care of specialized oncology centers.
Carvykti is currently approved in the United States for patients with multiple myeloma that has either relapsed or become resistant following initial therapy. While CAR-T therapies like Carvykti are highly personalized and complex, requiring precise administration and post-treatment monitoring, J&J believes now is the right time to reach patients directly.
Breaking Barriers in Cancer Treatment Awareness
According to June Lanoue, the head of U.S. hematology at J&J, the company’s aim is to extend knowledge of CAR-T therapy beyond academic institutions where such treatments are typically offered. “The actual awareness level of these options is very low,” Lanoue explained. “In the community, if they’re not able to get it, doctors are not talking about it and therefore they don’t have visibility to having a new option.”
Lanoue noted that nearly half of patients with relapsed or refractory multiple myeloma are treated at community oncology centers where awareness of CAR-T treatments remains limited. By targeting these patients directly, J&J hopes to empower them to seek out potentially life-extending therapies like Carvykti.
Confidence in Manufacturing Capabilities
J&J’s decision to roll out a DTC campaign also signals its growing confidence in its manufacturing capabilities. Earlier in Carvykti’s commercial journey, the company faced significant production hurdles that restricted supply and delayed treatment. Bristol Myers Squibb, which markets a competing CAR-T therapy called Abecma, faced similar issues.
“We feel very confident around production,” Lanoue said. “Treatment sites can order Carvykti without any constraint.” This assurance comes at a critical time, as the company looks to scale access in response to growing interest and demand.
Regulatory Support Enables Broader Access
The timing of the campaign is strategic, coinciding with recent regulatory changes by the U.S. Food and Drug Administration (FDA) aimed at easing access to CAR-T therapies. The FDA has reduced the side-effect reporting requirements and shortened the mandatory observation period following treatment. Additionally, patients are now allowed to resume activities like driving sooner than before.
“We think it will give more opportunity to more patients who live at a little bit further distance to be able to receive Carvykti,” Lanoue added, referencing the logistical barriers that previously limited patient eligibility.
Introducing ‘Marvin’—A Composite Patient Profile
J&J’s new 120-second advertisement introduces viewers to “Marvin,” a fictional character designed to represent the real-life struggles of patients dealing with multiple myeloma. The ad highlights the ongoing burden of traditional treatments involving frequent pills and injections. In contrast, Carvykti is portrayed as a single-infusion therapy offering the potential for long-term remission.
Recent clinical data appears to support these claims. In an early trial involving approximately 100 patients, one-third of those treated with Carvykti had not experienced disease progression five years post-treatment. This promising outcome was also featured in a New York Times article published in June, which significantly boosted patient inquiries about the therapy.
Targeted, Not Traditional, Marketing
While J&J has not disclosed the exact budget for the campaign, Lanoue emphasized that the spend is “significantly less” than what is typically invested in traditional TV advertising. “This is not a share of voice play; this is ultra targeted,” she explained.
The ad is designed to reach a highly specific audience—patients who may benefit most from Carvykti but are unlikely to learn about it through conventional medical channels. By focusing on streaming services and digital platforms, J&J aims to efficiently connect with these individuals.
Strong Sales and Future Projections
J&J reported $439 million in Carvykti sales during the second quarter of the year, with expectations that annual sales could eventually surpass $5 billion. These optimistic projections underscore the company’s belief in the therapy’s potential and its readiness to meet increasing demand.
The ad campaign also reflects a broader shift in how pharmaceutical companies are approaching patient engagement. As advanced therapies like CAR-T become more mainstream, companies are exploring innovative ways to inform and empower the public.
This article is inspired by content from Original Source. It has been rephrased for originality. Images are credited to the original source.